Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for
            <i>EGFR</i>
            -Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA

Tsuboi, Masahiro; Weder, Walter; Escriu, Carles; Blakely, Collin M.; He, Jianxing; Đačić, Sanja; Yatabe, Yasushi; Zeng, Leilei; Walding, Andrew; Chaft, Jamie E.

doi:10.2217/fon-2021-0549

Cited by 107 publications

(65 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Chen et al (2021) has reported the clinical efficacy of a stage IIIa NSCLC patient who received osimertinib as neoadjuvant therapy in combination with radiotherapy followed by surgery ( Chen et al, 2021 ). A phase 3 NeoADAURA study has been initiated in 2020 to evaluate the safety and efficacy of neoadjuvant osimertinib alone or in combination with chemotherapy compared to chemotherapy alone for patients with stage II-IIIb EGFR-mutated NSCLC ( Tsuboi et al, 2021 ). Recently, a phase II clinical trial evaluating the efficacy and safety of neoadjuvant osimertinib (80 mg QD for 6 weeks) for resectable EGFR-mutated lung adenocarcinoma (NEOS study) updated its findings at the 2022 ELCC meeting.…”

Section: Discussionmentioning

confidence: 99%

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series

Ren

Tong

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Evidence of osimertinib as neoadjuvant therapy for resectable non-small cell lung cancer (NSCLC) are currently lacking. This case series study aimed to assess the safety and feasibility of neoadjuvant osimertinib therapy followed by surgery for resectable NSCLC.Materials and methods: Patients with resectable NSCLC with epidermal growth factor receptor (EGFR) mutation who received osimertinib as neoadjuvant therapy followed by surgery at our center were included. Demographic features, radiologic and pathological assessment of response, surgery-related details and complications, toxicity profiles, and prognostic outcomes were extracted.Results: A total of 13 patients were included in this study. The median age at the time of surgical resection was 57 years (interquartile range: 52–64 years), and eight (61.5%) patients were female. The objective response rate (ORR) was 69.2% (9/13), and the complete resection rate was 100%. The rates of pathologic downstaging and lymph node downstaging were 100% (13/13) and 66.7% (6/9), respectively. There were no perioperative deaths and only three (23.1%) patients had postoperative complications. Seven (53.8%) and 13 (100%) patients experienced grade 1 treatment-related adverse reactions and laboratory abnormalities, respectively. No patients experienced drug withdrawal or surgical delays due to the adverse events. No patients showed grade 2 or worse toxicity profiles. One patient was lost to follow-up. The other 12 patients were alive and free of disease recurrence with a median follow-up time of 9.5 months.Conclusion: Neoadjuvant osimertinib therapy seemed to be safe and feasible for resectable EGFR-mutated NSCLC. Future large prospective studies are warranted to confirm whether osimertinib as neoadjuvant therapy outperforms standard tyrosine kinase inhibitors (TKIs) or chemotherapy for resectable EGFR-mutated NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series

Ren

Tong

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…However, in a neoadjuvant setting, it is still not clear whether EGFR-TKIs or immunotherapy should be given in the first place to those with EGFR mutations. The Phase III NeoADAURA study will evaluate the efficacy and safety of neoadjuvant osimertinib in patients with resectable EGFR-mutant NSCLC ( 17 ). In the current study, we have reported a stage IIIA EGFR mutant NSCLC with high PD-L1 expression, for whom nivolumab plus chemotherapy brought little benefit.…”

Section: Discussionmentioning

confidence: 99%

Case Report: An “Immune-Cold” EGFR Mutant NSCLC With Strong PD-L1 Expression Shows Resistance to Chemo-Immunotherapy

Zhao

Zhang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Long-term survival benefit has been noticed in non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs), such as PD-1 inhibitors. However, it is still controversial whether patients with EGFR-activating mutations may benefit from ICIs. Recently, in stage IIIA NSCLC, chemo-immunotherapy has led to significant pathological response, yet patients with the presence of known EGFR mutations were excluded from some randomized trials of neoadjuvant therapy. Herein, we report a case of a 50-year-old female patient, who was initially diagnosed as stage IIIA lung squamous cell carcinoma. Immunohistochemistry analysis showed that the patient presented with high PD-L1 expression. Then, chemo-immunotherapy was given to the patient but the disease progressed quickly with distant metastasis. A re-biopsy revealed a poorly differentiated lung adenocarcinoma together with EGFR p.L858R mutation. Then the patient received gefitinib, which resulted in significant regression of primary lung lesion. A detailed examination of pre-treatment tumor sections demonstrated rare infiltration of CD8+ T cells, indicating that the current patient presented with an “immune-cold” microenvironment, which might explain the primary resistance to chemo-immunotherapy. Taken together, our case indicated that comprehensive detection of PD-L1 expression, driver gene status, together with tumor immune microenvironment, may offer a better prediction of treatment efficacy.

show abstract

“…In the NeoADAURA trial, patients with resectable II-IIIB N2 disease will be enrolled for either neoadjuvant osimertinib with or without chemotherapy versus neoadjuvant chemotherapy. MPR is the primary endpoint [ 63 ].…”

Section: Stage Iiia-n2 Diseasementioning

confidence: 99%

Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer

Allaeys

Berzenji

Lauwers

et al. 2022

Cancers

View full text Add to dashboard Cite

For patients with locally advanced non-small cell lung cancer (NSCLC) or positive N1 nodes, multimodality treatment is indicated. However, the optimal management of patients presenting with ipsilateral positive mediastinal nodes (N2 disease) has not been determined yet. Different treatment regimens consisting of chemotherapy, radiation therapy, and surgery have been proposed and implemented previously. In more recent years, immunotherapy and targeted therapies have been added as therapeutic options. The role of surgery is currently redefined. Recent studies have shown that surgical resection after induction immunotherapy or targeted therapy is feasible and yields good short-term results. In this review, we summarize the latest data on multimodality treatment options for stage IIIA-N2 locally advanced NSCLC, depending on the extent of nodal involvement.

show abstract

Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for EGFR -Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA

Cited by 107 publications

References 48 publications

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series

Case Report: An “Immune-Cold” EGFR Mutant NSCLC With Strong PD-L1 Expression Shows Resistance to Chemo-Immunotherapy

Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About